Y-Mabs Therapeutics Welcomes New CFO Amid Strategic Shift
Company Announcements

Y-Mabs Therapeutics Welcomes New CFO Amid Strategic Shift

An update from Y-Mabs Therapeutics (YMAB) is now available.

Y-mAbs Therapeutics, Inc. has appointed Peter Pfreundschuh as its new Chief Financial Officer and Treasurer, bringing a wealth of biotech finance experience from his previous leadership roles. Pfreundschuh is taking over from Bo Kruse and is set to receive a competitive package including a $500,000 salary, stock options, bonuses, and comprehensive benefits. His appointment is framed within an employment agreement that details severance benefits under various conditions, underscoring the company’s strategic financial leadership transition.

For detailed information about YMAB stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskY-mAbs Reports Third Quarter 2024 Financial Results
TheFlyMorning Movers: Expedia, Airbnb moving in opposite directions after results
TheFlyY-mAbs Therapeutics reports Q3 EPS (16c), consensus (16c)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App